SCHEMBL14304553

SCHEMBL14304553

N#Cc1cccc2c1CCO2

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ITGB2 P05107 1/20 0.39
ICAM1 P05362 1/20 0.39
ITGAL P20701 1/20 0.39
KMT2A Q03164 2/20 0.37
MEN1 O00255 1/20 0.37
NPC1 O15118 1/20 0.36
RAB9A P51151 1/20 0.36
TRPA1 O75762 2/20 0.36
NOTUM Q6P988 1/20 0.36
LMNA P02545 2/20 0.35
CRHBP P24387 2/20 0.35
CRHR2 Q13324 2/20 0.35
SMN1; SMN2 Q16637 2/20 0.35
HTT P42858 1/20 0.35
SLC9A1 P19634 2/20 0.35
MTNR1B P49286 4/20 0.35
EGFR P00533 1/20 0.35
TSHR P16473 1/20 0.34
KIF11 P52732 1/20 0.34
SLC9A5 Q14940 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30289551 0.89 ITGB2 (0.37) ITGB2ICAM1ITGALKMT2ANPC1
SCHEMBL21224311 0.89 ITGB2 (0.37) ITGB2ICAM1ITGALKMT2ANPC1
SCHEMBL17240293 0.82 ITGB2 (0.38) ITGB2ICAM1ITGALKMT2AMEN1
SCHEMBL7128133 0.81 TRPA1 (0.34) KMT2AMEN1TRPA1NOTUMLMNA
SCHEMBL21800420 0.77 PNMT (0.44) ITGB2ICAM1ITGALKMT2ANPC1
SCHEMBL1091335 0.77 GRM5 (0.39) ITGB2ICAM1ITGALKMT2ANPC1
SCHEMBL7128137 0.76 ITGB2 (0.44) ITGB2ICAM1ITGALKMT2ANPC1
SCHEMBL7701503 0.75 MTNR1B (0.39) ITGB2ICAM1ITGALKMT2AMEN1
SCHEMBL23706922 0.74 ITGB2 (0.39) ITGB2ICAM1ITGALKMT2AMEN1
SCHEMBL4046832 0.73 TRPA1 (0.37) NPC1RAB9ATRPA1TSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4185386-B1 HETEROCYCLIC INHIBITORS OF TEAD FOR TREATING CANCER GENENTECH INC (US) 2025-01-08 EP claimed
US-12275745-B2 Therapeutic compounds and methods of use GENENTECH, INC. (US) 2025-04-15 US disclosed
WO-2023222124-A1 5,6-DIHYDRO-1,2,4-TRIAZINE COMPOUND AND PHARMACEUTICAL USE THEREOF AS GLP-1 RECEPTOR AGONIST 中国科学院上海药物研究所 2023-11-23 WO disclosed
CN-116234797-A Heterocyclic inhibitors of TEAD for the treatment of cancer 基因泰克公司 2023-06-06 CN disclosed
WO-2008005368-A2 PIPERAZINES AS P2X7 ANTAGONISTS ABBOTT LABORATORIES (US) 2008-01-10 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12275745-B2 Therapeutic compounds and methods of use VHL, TP53, MCL1 ITGB2 2486/4885ICAM1 1154/4885ITGAL 2894/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.